ClinicalTrials.gg
RecruitingNCT05679284Updated Jun 1, 2023

A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs

An observational study in Drug Abuse, Intravenous, Substance Dependence and Needle Injury, sponsored by Tampere University Hospital. Recruiting at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.

Sponsored by Tampere University Hospital · Observational

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

In addition to the well-known toxicological harms of intravenous drug (IVD) use, there can also be local tissue complications, including infections, venous sclerosis, tissue necrosis, and drug needle fragment retentions. Drug needle fragments in subcutaneous tissue may cause local symptoms (usually pain and infections), but they have also been identified as causing emboli to organs. The literature has described numerous case reports of people who inject drugs (PWIDs) and have retained needle fragments. The prevalence of the condition is not known, and the researchers therefore aim to perform the first cross-sectional study of PWIDs to estimate how common needle fragment retentions are and what their risk factors are in this population.

Read the detailed description

The clinical significance of retained needle fragments remains unknown. Needle retentions can be asymptomatic, cause local symptoms, and can sometimes even lead to dangerous complications such as needle emboli to the heart or lungs. The most common injection sites are likely the peripheral veins of the arms. However, continuous IVD use leads to vein sclerosis, and patients with long-term use may therefore also use peripheral veins of their lower limbs and even the central veins of the groin or neck. Subcutaneously retained needles can pose a risk of needlestick injury to medical staff during clinical examination and treatment procedures. Unrecognized retained needles can also cause hazards during magnetic resonance imaging.

The study protocol received a positive review from the Tampere University Hospital Ethics Committee (study code: R22037). The researchers subsequently received the organizational permissions necessary to conduct the study. PWIDs will be asked to give written informed consent prior to any study procedures. Participants will be asked to fill in a questionnaire about their basic information, drug use history, previous injection sites, and whether they have had any local complications due to injecting drugs. After the completion of the questionnaire, participants will undergo targeted X-ray imaging of the injection sites. As metallic objects, needle fragments can be visualized with standard X-ray imaging. Female participants of childbearing potential (\< 50 years) will undergo urine sample pregnancy testing prior to X-ray imaging. A pilot study with 20 participants will be conducted first. Experiences from the pilot will be used to refine the study protocol if needed. If modifications are made, they will be subjected to ethics review and will be provided on ClinicalTrials.gov. After the pilot study, the researchers aim to recruit an additional 80 patients (totaling up to 100 participants).

Our research questions are 1) What is the prevalence of radiologically confirmed needle retention among PWIDs*? The secondary research questions are

  1. Do patient-reported symptoms and the suspicion of a retained needle fragments correspond to radiologically confirmed needle retention?
  2. What are the predisposing factors to needle fragmentation?
  3. Have PWIDs sought medical attention prior to the study for possible symptoms in the injection sites?
  4. How frequently are verified needle fragments surgically removed within five years after their detection, and are verified needle fragments a proxy or a risk factor for mortality? *As only patients in outpatient care will be recruited, the sample is not entirely representative of all PWIDs in the study area (e.g., people who are hospitalized or imprisoned are not recruited).
02

Conditions studied

  • Drug Abuse, Intravenous
  • Substance Dependence
  • Needle Injury
  • Soft Tissue Injuries
  • Foreign Bodies

Keywords

  • Intravenous drug use
  • needle retention
  • needle fragment
03

In context

Substance Abuse, Intravenous

32 studies on the registry are indexed under Substance Abuse, Intravenous; 1 is open to participants now.

Browse Substance Abuse, Intravenous studies →

Lead sponsor

Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The population base is the adult IVD users from the drug abuse treatment centres in Tampere, Finland.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of intravenous drug use
  • Current treatment of the drug abuse problem at a local low-threshold drug abuse service unit or primary health care centre.
  • Adherence to fill in the questionnaire
  • Participation to X-ray imaging of injection sites

Exclusion criteria

Exclusion Criteria:

  • No history of intravenous drug use
  • Does not adhere to fill in the questionnaire or refuses X-ray imaging
  • Pregnancy
  • Underage (18 years old)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cases: Intravenous drug users with drug needle fragment retentions

    All intravenous drug users from the service units will be asked to participate. X-ray imaging has the goal to identify patients with needle fragment retentions in subcutaneous tissue.

    Radiation: Low-dose X-ray of subcutaneous tissues

  • Controls: Intravenous drug users without drug needle fragment retentions

    All intravenous drug users from the service units will be asked to participate. Control group consists of those with no radiologically confirmed subcutaneous needle fragment retentions.

    Radiation: Low-dose X-ray of subcutaneous tissues

Interventions

  • RadiationLow-dose X-ray of subcutaneous tissues

    To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.

06

What researchers measure

Primary outcomes

  1. Prevalence of needle fragment retentions among intravenous drug users.

    The prevalence of needle fragment retentions among intravenous drug users. The number of individuals with at least one radiologically confirmed needle fragment in subcutaneous tissue over the total number of participants.

    Time frame: An average of 2 years.

  2. Risk factors for needle fragment retentions in a cross-sectional design

    Risk factors for needle fragment retentions in a cross-sectional design. Patient characteristics as risk factors for having subcutaneous needle fragment retentions.

    Time frame: An average of 2 years.

  3. The proportion of patients with surgically removed needle fragment retentions at five years of follow-up.

    The proportion of patients with surgically removed needle fragment retentions after five years of follow-up. Patients with needle fragment retentions will be referred to the surgical clinic and will be prospectively followed up through healthcare records.

    Time frame: Up to 5 years.

07

Study locations

1 of 1 sites recruiting
  • Hatanpää Health Center
    Tampere, Finland
    Recruiting
    • · Contact040 8063649
08

References and documents

Individual participant data

Plan to share: No — No plans to share individual-level data with other investigators.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05679284
Collaborators
Deaconess Foundation, A-Clinic Foundation
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
May 25, 2023
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Jun 1, 2023

Study contacts

Otso Arponen, Associate Professor, MD
Contact
otso.arponen@tuni.fi
+358 50 410 6170
Otso Arponen, MD-PhD
study chair · Pirkanmaa Hospital District (PSHP)
Olli PO Nevalainen, MD-PhD
study chair · City of Tampere; Tampere University; Pirkanmaa Hospital District (PSHP).
Irina Rinta-Kiikka, MD-PhD
study chair · Tampere University Hospital
Heidi Laukkala, MD
study chair · City of Tampere, Tampere University
Markku Sumanen, MD-PhD
principal investigator · Tampere University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion